L19-IL2

Interleukin-2 fused to the L19 antibody (L19-IL2) · Philogen S.p.A.

Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for L19-IL2, covering 2014-02-25 to 2026-01-14. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors [Phase 1]

See pricing